Myriad Genetics MYGN
-
New Morningstar Analyst Report - Myriad Genetics
… off its pharmaceuticals segment, Myriad Genetics could garner a hefty takeover premium ..... dividend payments in the future. Myriad Genetics develops and markets cancer-related ..... has had to date with BRACAnalysis. Myriad Genetics ' predictive medicine business has …
-
Maintaining Myriad's Fair Value Estimate Following a Strong Fiscal Third Quarter
Myriad Genetics MYGN reported third-quarter results that beat our expectations, as sales of BRACAnalysis contributed to the firm's $130 million …
-
Keryx: A Biotech For Aggressive Investors
By Mel Daris : Over the past few years, Keryx Biopharmaceuticals ( KERX ) has been working on new anti-cancer drugs aimed at stopping the spread of several types of cancer including colorectal and myeloma. These drugs, specifically KRX-0401 (perifosine), are still in Phase 1, 2 and 3 trial phases,
-
No Fair Value Estimate Changes for Diagnostic Firms, Despite Negative Supreme Court Ruling
… Laboratories were invalid, sparking concern that patents on tests from other diagnostic firms--in particular Myriad Genetics MYGN --could be vulnerable to a similar fate. While nine of Myriad's patents could also be reviewed by the Supreme …
-
The Supreme Court's decision to reject Prometheus Labs' (NSRGY.PK) testing patents has wider industry implications and could be a setback for other biotechs that sell diagnostic devices, including ...
… PK ) testing patents has wider industry implications and could be a setback for other biotechs that sell diagnostic devices, including Roche ( RHHBY.PK ), Abbot ( ABT +0.3% ) and Myriad Genetics ( MYGN -5.4% ) Post your comment!
-
UnitedHealth (UNH) issues a report (.pdf) on the potential of genetic testing that indicates the industry could grow to $25 annually - after the technology only generated $5B in 2010. Leerink Swann ...
… technology only generated $5B in 2010. Leerink Swann analyst Daniel Leonard tips off Genomic Health ( GHDX ) and Myriad Genetics ( MYGN ) as two companies that could benefit from a surge in the tests used to detect cancers and infectious diseases …
-
Myriad Reports Strong Fiscal 2Q; Raised Guidance Now In Line With Our Forecast
We're maintaining our fair value estimate for Myriad Genetics MYGN following another strong quarter for the firm's flagship BRACAnalysis test. Myriad's total revenue grew 22% year over year …
-
UPDATE 1- Myriad Genetics Q2 beats; raises FY12 outlook
Jan 31 (Reuters) - Myriad Genetics Inc posted better-than-expected quarterly results and raised its 2012 outlook on strong demand for its diagnostic tests for cancer, sending its shares up 4 percent in after-market trading.
-
Behind Roche's Pharmaceutical Shake Up
By Jessica King Holden : Roche's ( RHHBY.PK ) hostile $5.7 billion bid for genetic diagnostic company Illumina ( ILMN ) has opened a pandora's box of genetic information. The pharmaceutical giant appears to be aligning itself to become a one-stop-shop for pharmaceutical success, avoiding the ...
-
Myriad Genetics , Inc. MYGN Q2 2012 Earnings Call Transcript
… and gentlemen, thank you for standing by. Welcome to the Myriad Genetics ' Fiscal First Quarter Earnings Call. During the presentation ..... Lindsey. Good afternoon, everyone, and welcome to the Myriad Genetics ' second fiscal quarter 2012 earnings call. During the …